Delfini is now 10! Come join us for our highly rated critical appraisal
training in beautiful Portland, Oregon: September 20th & 21st. Spaces are
limited. http://www.delfini.org/page_Delfini_Seminars.htm
What's New at delfini.org (and there is more at delfini.org/blog):
Since our last DelfiniGram, the entries below are available at
http://www.delfini.org/delfiniNew.htm—
08/01/2012: COGENT Study (Clopidogrel and the Optimization of
Gastrointestinal Events Trial) Evidence Review by Brian Chou, 2014 PharmD
Candidate
07/24/2012: Update on Decision Support for Clinicians and Patients
07/17/2012: Early Termination of Clinical Trials—2012 Update
07/10/2012: CONSORT Update of Abstract Guidelines 2012
07/02/2012: Obtaining Absolute Risk Reduction (ARR) and Number Needed To
Treat (NNT) From Relative Risk (RR) and Odds Ratios (OR) Reported in
Systematic Reviews
06/26/2012: Are Adaptive Trials Ready For Primetime?
06/06/2012: Biologics Saftey Review—An abstract of ours was selected for
publication by the The European League Against Rheumatism (EULAR) for
their Annual European Congress of Rheumatism 2012. We believe that our
review provides important safety information for providers and patients.
While the evidence has to be considered borderline at best due to study
design and methodology issues (much is observational, for example), we
believe the patterns are highly compelling, consistent and that they are
not likely to be explained by a systematic bias. Therefore, we feel quite
confident in the direction of the outcomes.
05/29/2012: Loss to Follow-up Update
05/22/2012: Adjusting for Multiple Comparisons
05/17/2012: Some Points About Surrogate Outcomes Courtesy of Steve Simon PhD
05/10/2012: Think you understand p-values? We thought we did too. We were
wrong. A huge number of us have been taught incorrectly. Thanks to Dr.
Brian Alper, Editor-in-Chief of DynaMed who brought this to our attention
and who, with some other writers, helped us work through the brambles. See
our new definitions and explanations of “p-value” and “confidence
intervals” in our glossary. We have also added some thinking about
“multiplicity testing.” Our tools have been updated to reflect these
changes so you may wish to download your favorites for validity anew. See
also our recommendation for DynaMed.
Updated tools include—
Delfini_Pearls_Analyzing_Results.doc & pdf
Delfini_Tool_StudyValidity_Usability.doc & pdf
Again, to access this information, go to
http://www.delfini.org/delfiniNew.htm. For seminar information, go to
http://www.delfini.org/page_Delfini_Seminars.htm.
Follow Us & Like Us!
Twitter: @delfinigroup
Facebook: http://www.facebook.com/delfinigroup
Michael E Stuart MD
President and Medical Director, Delfini Group
Clinical Asst Professor, UW School of Medicine
6831 31st Ave N.E.
Seattle, Washington 98115
206-854-3680 Mobile Phone
206-527-6146 Home Office
[log in to unmask]
www.delfini.org
|